[go: up one dir, main page]

BR112018000297A2 - polimorfo de macrociclo de diarila - Google Patents

polimorfo de macrociclo de diarila

Info

Publication number
BR112018000297A2
BR112018000297A2 BR112018000297A BR112018000297A BR112018000297A2 BR 112018000297 A2 BR112018000297 A2 BR 112018000297A2 BR 112018000297 A BR112018000297 A BR 112018000297A BR 112018000297 A BR112018000297 A BR 112018000297A BR 112018000297 A2 BR112018000297 A2 BR 112018000297A2
Authority
BR
Brazil
Prior art keywords
polymorph
macrocycle
diaryl
diaryl macrocycle
macrocycle polymorph
Prior art date
Application number
BR112018000297A
Other languages
English (en)
Inventor
W Rogers Evan
J Cui Jingrong
Original Assignee
Tp Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tp Therapeutics Inc filed Critical Tp Therapeutics Inc
Publication of BR112018000297A2 publication Critical patent/BR112018000297A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Indole Compounds (AREA)
BR112018000297A 2015-07-06 2016-07-05 polimorfo de macrociclo de diarila BR112018000297A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562188846P 2015-07-06 2015-07-06
US201562218672P 2015-09-15 2015-09-15
PCT/US2016/040972 WO2017007759A1 (en) 2015-07-06 2016-07-05 Diaryl macrocycle polymorph

Publications (1)

Publication Number Publication Date
BR112018000297A2 true BR112018000297A2 (pt) 2018-09-04

Family

ID=57685592

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018000297A BR112018000297A2 (pt) 2015-07-06 2016-07-05 polimorfo de macrociclo de diarila

Country Status (25)

Country Link
US (5) US10294242B2 (pt)
EP (2) EP3319969B1 (pt)
JP (2) JP6917974B2 (pt)
KR (1) KR102623734B1 (pt)
CN (2) CN113354653B (pt)
AU (1) AU2016289454B2 (pt)
BR (1) BR112018000297A2 (pt)
CA (1) CA2990020C (pt)
DK (1) DK3319969T3 (pt)
ES (1) ES2979111T3 (pt)
FI (1) FI3319969T3 (pt)
HK (1) HK1254492A1 (pt)
HR (1) HRP20240780T1 (pt)
HU (1) HUE067352T2 (pt)
IL (2) IL256443B (pt)
LT (1) LT3319969T (pt)
MX (2) MX386680B (pt)
PL (1) PL3319969T3 (pt)
PT (1) PT3319969T (pt)
RS (1) RS65593B1 (pt)
RU (1) RU2765181C2 (pt)
SI (1) SI3319969T1 (pt)
SM (1) SMT202400213T1 (pt)
WO (1) WO2017007759A1 (pt)
ZA (1) ZA201708436B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110317214B (zh) 2014-01-24 2022-11-22 特普医药公司 作为蛋白质激酶的调节剂的二芳基巨环
US10316044B2 (en) 2015-07-02 2019-06-11 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
RU2765181C2 (ru) * 2015-07-06 2022-01-26 Тёрнинг Поинт Терапьютикс, Инк. Полиморфная форма диарильного макроцикла
EP4480543A3 (en) * 2015-07-21 2025-02-12 Turning Point Therapeutics, Inc. Chiral diaryl macrocycle and use thereof in the treatment of cancer
CN109715165A (zh) 2016-07-28 2019-05-03 Tp生物医药公司 巨环激酶抑制剂
TWI808958B (zh) * 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CN107586796B (zh) * 2017-07-20 2021-08-06 暨明医药科技(苏州)有限公司 (r)-2-(1-氨基乙基)-4-氟苯酚的合成方法
AU2018306328B2 (en) 2017-07-28 2023-03-09 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
JOP20200152A1 (ar) 2017-12-19 2022-10-30 Turning Point Therapeutics Inc مركبات حلقية كبرى لعلاج مرض
CN110386944B (zh) * 2018-04-16 2021-10-29 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的二(杂)芳基大环化合物
SI3870579T1 (sl) 2018-10-22 2025-03-31 Alumis Inc. Inhibitorji tyk2 in njihova uporaba
WO2020233645A1 (zh) 2019-05-21 2020-11-26 浙江海正药业股份有限公司 大环类衍生物、及其制备方法和用途
PH12021553174A1 (en) * 2019-06-19 2022-08-01 Turning Point Therapeutics Inc Polymorphs of a macrocyclic kinase inhibitor
TW202133855A (zh) 2019-11-27 2021-09-16 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
KR20220134522A (ko) 2019-11-27 2022-10-05 터닝 포인트 테라퓨틱스, 인크. 디아릴 매크로시클릭 화합물을 수반하는 병용 요법
IL295938A (en) * 2020-03-02 2022-10-01 Turning Point Therapeutics Inc Therapeutic uses of macrocyclic compounds
WO2021223748A1 (zh) * 2020-05-08 2021-11-11 山东轩竹医药科技有限公司 大环类酪氨酸激酶抑制剂的晶型及其制备方法
CN112174982A (zh) * 2020-09-10 2021-01-05 上海希迈医药科技有限公司 一种洛普替尼晶型及其制备方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4838925A (en) 1986-04-25 1989-06-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
EP0281841B1 (de) 1987-03-07 1990-11-14 Bayer Ag Verfahren zur Herstellung von 5-Amino-4,6-dihalogenpyridinen
DE69425736T2 (de) 1993-03-25 2001-04-12 Pharmacia & Upjohn Co., Kalamazoo Formyl- oder Cyano- substituierte Indolderivate mit dopaminergischer Wirkung
HU219709B (hu) 1993-12-07 2001-06-28 Eli Lilly And Co. Proteinkináz C gátló hatású kondenzált indolszármazékok, eljárás előállításukra, és az ezeket tartalmazó gyógyászati készítmények
GB9403639D0 (en) 1994-02-25 1994-04-13 Boots Co Plc Therapeutic agents
FR2746309B1 (fr) 1996-03-22 1998-04-17 Oreal Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
FR2793791B1 (fr) 1999-05-19 2002-01-25 Univ Paris 7 Denis Diderot Nouveaux composes inhibiteurs specifiques de phospholipases a2
AU8395501A (en) 2000-07-31 2002-02-13 Hoffmann La Roche Piperazine derivatives
DE60112611T2 (de) 2000-12-08 2006-06-14 Ortho Mcneil Pharm Inc Makroheterocyclische verbindungen als kinase inhibitoren
AU2002254114A1 (en) 2001-03-23 2002-10-08 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
WO2003011222A2 (en) * 2001-07-27 2003-02-13 Merck & Co., Inc. Thrombin inhibitors
EP1402888A1 (en) * 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
US8005919B2 (en) 2002-11-18 2011-08-23 Aol Inc. Host-based intelligent results related to a character stream
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
UA91698C2 (ru) * 2005-01-10 2010-08-25 Арена Фармасьютікалз, Інк. Комбинированная терапия для лечения диабета и родственных ему состояний и для лечения состояний, улучшенных увеличением уровня glp-1 крови
US8960547B2 (en) 2007-09-19 2015-02-24 E-Seek, Inc. Document scanner with instant retrieval process
US8270176B2 (en) 2008-08-08 2012-09-18 Stats Chippac Ltd. Exposed interconnect for a package on package system
TWM352384U (en) 2008-08-22 2009-03-11 Luff Technology Co Ltd Wireless detection device for club and system thereof
JP5749645B2 (ja) 2008-09-08 2015-07-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung タンパク質キナーゼ阻害剤としての大環状ピリミジン
CA2738026C (en) 2008-09-22 2017-01-24 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
AU2009308465B2 (en) 2008-10-22 2015-02-12 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as TRK kinase inhibitors
PE20110828A1 (es) 2008-10-31 2011-11-22 Genentech Inc Compuestos de pirazolopirimidina como inhibidores de jak
WO2010063487A1 (en) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
CN102574854B (zh) 2009-10-13 2014-04-16 伊兰科动物健康爱尔兰有限公司 大环整合酶抑制剂
JP5643332B2 (ja) 2009-12-07 2014-12-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピロロピリジンまたはベンゾイミダゾールコアを含有する複素環化合物
JP2013512952A (ja) 2009-12-07 2013-04-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インドールコアを含有する複素環化合物
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
DK2918588T3 (en) 2010-05-20 2017-08-28 Array Biopharma Inc Macrocyclic compounds as TRK kinase inhibitors
GB2482674B (en) 2010-08-09 2012-08-22 Rolls Royce Plc An aerofoil, an aerofoil sub-assembly and a method of making the same
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
EP2541470B1 (en) 2011-06-29 2017-10-04 Denso Wave Incorporated Information code and information code reader
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
RU2014110399A (ru) * 2011-08-19 2015-09-27 Мерк Шарп И Доум Корп. Кристаллические формы вгс протеазного ингибитора
WO2013045702A2 (en) 2011-09-29 2013-04-04 L'oreal Dye composition comprising a non-glycosyl iridoid compound and a specific nucleophile or an amino or thio polymer, dyeing process, and device therefor
WO2013045701A2 (en) 2011-09-29 2013-04-04 L'oreal Dyeing process using a composition comprising a glycosyl iridoid compound and a nucleophile or an amino or thio polymer, composition and devices therefor
CN103930427B (zh) 2011-09-30 2016-03-09 昂科迪塞恩股份有限公司 大环flt3激酶抑制剂
CA2852936A1 (en) 2011-10-20 2013-04-25 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
CN104169286B (zh) 2012-03-06 2016-06-08 辉瑞大药厂 用于治疗增殖性疾病的大环衍生物
KR102085121B1 (ko) * 2012-03-09 2020-03-05 렉시컨 파마슈티컬스 인코퍼레이티드 이미다조[1,2-b]피리다진계 화합물, 그를 포함하는 조성물 및 그의 용도
JP6418950B2 (ja) 2012-03-09 2018-11-07 レクシコン ファーマシューティカルズ インコーポレイテッド ピラゾロ[1,5−a]ピリミジン系化合物、それを含む組成物、及びそれらを使用する方法
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
HK1215250A1 (zh) 2013-01-30 2016-08-19 Bayer Pharma Aktiengesellschaft 氨基取代的异噻唑
CN105358534A (zh) 2013-04-23 2016-02-24 斯洛文尼亚莱柯制药股份有限公司 8-氯-1-甲基-苯并[d]吖庚因的新合成方法、新的中间体及其生产方法
EP3026051A4 (en) 2013-07-24 2017-03-08 Takeda Pharmaceutical Company Limited Heterocyclic compound
US20150112816A1 (en) * 2013-10-21 2015-04-23 Disney Enterprises, Inc. Systems and methods for providing a graphical user interface for providing brand integration within online content, managing brand integration within online content, and/or managing compensation associated with online content
WO2015073267A1 (en) 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CN110317214B (zh) 2014-01-24 2022-11-22 特普医药公司 作为蛋白质激酶的调节剂的二芳基巨环
BR202014004079U2 (pt) 2014-02-21 2015-10-27 Mix For You Ltda higienizador íntimo
WO2016070241A1 (en) 2014-11-03 2016-05-12 Ctxt Pty Ltd Triazine compounds, compositions and synthesis
CN107207514B (zh) 2014-12-15 2020-01-24 康联制药有限公司 稠环杂芳基化合物及其作为trk抑制剂的用途
ES2928084T3 (es) 2015-02-20 2022-11-15 Rigel Pharmaceuticals Inc Inhibidores de GDF-8
EP3246346B1 (en) 2015-03-09 2020-01-01 Sumitomo Rubber Industries, Ltd. Tire
US10329294B2 (en) 2015-03-12 2019-06-25 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of IRAK4 activity
WO2016144844A1 (en) 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Carboxamide inhibitors of irak4 activity
CR20170509A (es) 2015-05-05 2018-04-16 Bayer Pharma AG Derivados de ciclohexano sustituido con amido
US10316044B2 (en) * 2015-07-02 2019-06-11 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
US9524416B1 (en) 2015-07-03 2016-12-20 Fingerprint Cards Ab Fingerprint sensing device comprising three-dimensional pattern
RU2765181C2 (ru) 2015-07-06 2022-01-26 Тёрнинг Поинт Терапьютикс, Инк. Полиморфная форма диарильного макроцикла
US10239565B2 (en) 2015-07-17 2019-03-26 John Michael Baker Pickup truck tailgate lifting apparatus
EP4480543A3 (en) * 2015-07-21 2025-02-12 Turning Point Therapeutics, Inc. Chiral diaryl macrocycle and use thereof in the treatment of cancer
KR20180102544A (ko) 2015-10-26 2018-09-17 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 Trk 억제제-내성 암에서의 점 돌연변이 및 이의 관련 방법
JP6580495B2 (ja) 2016-02-02 2019-09-25 三菱重工業株式会社 保持治具
EP3423435B1 (en) 2016-03-04 2023-08-23 Vanderbilt University Substituted indole mcl-1 inhibitors
US10632076B2 (en) 2016-11-18 2020-04-28 Fertin Pharma A/S Tablet comprising separate binder and erythritol
EP3555137A1 (en) 2016-12-14 2019-10-23 Development Center for Biotechnology Antibody-drug conjugates and uses thereof

Also Published As

Publication number Publication date
HK1254492A1 (zh) 2019-07-19
HRP20240780T1 (hr) 2024-09-13
KR102623734B1 (ko) 2024-01-10
HUE067352T2 (hu) 2024-10-28
JP6917974B2 (ja) 2021-08-11
RS65593B1 (sr) 2024-06-28
US20210094974A1 (en) 2021-04-01
LT3319969T (lt) 2024-06-10
IL256443A (en) 2018-02-28
MX2017017081A (es) 2018-08-16
ZA201708436B (en) 2021-03-31
PT3319969T (pt) 2024-06-17
RU2018104269A (ru) 2019-08-06
AU2016289454A1 (en) 2018-01-04
FI3319969T3 (fi) 2024-06-13
EP3319969B1 (en) 2024-04-03
EP3319969A1 (en) 2018-05-16
US20250223298A1 (en) 2025-07-10
JP2021119151A (ja) 2021-08-12
RU2018104269A3 (pt) 2019-12-17
CN108026108B (zh) 2021-06-22
RU2765181C2 (ru) 2022-01-26
JP2018529633A (ja) 2018-10-11
IL283184B2 (en) 2023-06-01
ES2979111T3 (es) 2024-09-24
SI3319969T1 (sl) 2024-09-30
US10294242B2 (en) 2019-05-21
DK3319969T3 (da) 2024-07-08
IL256443B (en) 2021-05-31
CN113354653B (zh) 2024-12-31
US20180194777A1 (en) 2018-07-12
JP7212713B2 (ja) 2023-01-25
SMT202400213T1 (it) 2024-07-09
CN108026108A (zh) 2018-05-11
PL3319969T3 (pl) 2024-06-24
US12187739B2 (en) 2025-01-07
EP4397665A3 (en) 2024-08-21
MX386680B (es) 2025-03-19
AU2016289454B2 (en) 2020-07-09
NZ738180A (en) 2024-04-26
CN113354653A (zh) 2021-09-07
WO2017007759A1 (en) 2017-01-12
IL283184A (en) 2021-06-30
US20230295184A1 (en) 2023-09-21
EP3319969A4 (en) 2019-07-03
KR20180026480A (ko) 2018-03-12
US20190233437A1 (en) 2019-08-01
CA2990020A1 (en) 2017-01-12
MX2021008145A (es) 2021-08-11
EP4397665A2 (en) 2024-07-10
CA2990020C (en) 2024-02-27

Similar Documents

Publication Publication Date Title
BR112018000297A2 (pt) polimorfo de macrociclo de diarila
MA54568A (fr) Substitutions de nucléotides prédéterminées
CL2016002129A1 (es) Compuestos de azolina
PT3298027T (pt) Compostos depsipéptidos antelmínticos
PL3386745T5 (pl) Powłoki barierowe
EP3313828A4 (en) METALLO-BETA-Lactamase INHIBITORS
EP3156789C0 (en) BIOSENSOR
PT4039675T (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
EP3305993A4 (en) CONSTRUCTION MACHINE
LT3464336T (lt) Junginiai
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
CL2016002165A1 (es) Compuestos de aminocarbonilcarbamato
DK3286260T3 (da) Polyolefinrør
HUE054351T2 (hu) Vegyületek
EP3387414A4 (en) BIOSENSOR
PT3131898T (pt) Derivados de fluoroalquilfluoreno
DK3597189T3 (da) Krystallinske forbindelser
BR112018001062A2 (pt) compostos inovadores
ES2789757T8 (es) Herramienta de conformado
HUE059063T2 (hu) Tumorellenes hatású vegyületek
ES1141731Y (es) Cepillo de Dientes
MA49708A (fr) Dérivés de dihétérocycle liés à cycloalkyle
LT3331885T (lt) Junginiai
EP3387316A4 (en) FALTENBALGZURÜCKHALTUNG
IT201600102119A1 (it) Seminatrice

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TURNING POINT THERAPEUTICS, INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]